Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3208
Title: Homografts versus stentless bioprosthetic valves in the pulmonary position: A multicentre propensity-matched comparison in patients younger than 20 years
Authors: Ward, C.
Sayed, S.
Dunne, B.
Whight, C.
Alphonso, N.
Andrews, D.
Venugopal, P.
Jalali, H.
Marathe, S. P.
Bell, D.
Betts, K.
Issue Date: 2019
Source: 56, (2), 2019, p. 377-384
Pages: 377-384
Journal: European Journal of Cardio-thoracic Surgery
Abstract: Objectives: The aim of this study was to compare the performance of pulmonary homografts with stentless bioprosthetic valves [Medtronic Freestyle™ (Medtronic, Minneapolis, MN, USA)] in the pulmonary position in patients with congenital heart disease (CHD) younger than 20 years. Methods: Between January 2000 and December 2017, 215 patients were retrospectively identified from hospital databases in 3 congenital heart centres in Australia. Valve performance was evaluated using standard criteria. Propensity score matching was used to balance the 2 treatment groups. Results: Freedom from reintervention for patients who received a pulmonary homograft (n = 163) was 96%, 88% and 81% at 5, 10 and 15 years and for patients who received a Freestyle™ valve (n = 52) was 98%, 89% and 31% at 5, 10 and 15 years, respectively. Freedom from structural valve degeneration for patients with a homograft was 92%, 87% and 77% at 5, 10 and 15 years and for patients with a Freestyle valve was 96%, 80% and 14% at 5, 10 and 15 years, respectively. In the first 10 years, there was no difference in outcomes [reintervention hazard ratios (HR) = 0.69, 95% confidence intervals (CI) (0.20-2.42), P = 0.56; structural valve degeneration HR = 0.92 (0.34-2.51), P = 0.87]. After 10 years, the recipients of the Freestyle valves were at higher risk of both outcomes [reintervention HR = 7.89; 95% CI (2.79-22.34), P < 0.001; structural valve degeneration HR = 7.41 (2.77-19.84), P < 0.001]. The findings were similar when analysed by implantation in the orthotopic position and in the propensity-matched groups. Conclusions: The Freestyle stentless bioprosthetic valve is a comparable alternative to cryopreserved pulmonary homografts up to 10 years after implantation when implanted in an orthotopic pulmonary position in patients younger than 20 years with CHD.L6294272682019-10-01
2019-10-08
DOI: 10.1093/ejcts/ezz021
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L629427268&from=exporthttp://dx.doi.org/10.1093/ejcts/ezz021 |
Keywords: Australia;child;clinical outcome;comparative study;congenital heart disease;controlled study;cryopreservation;factual database;female;human;major clinical study;male;multicenter study (topic);observational study;orthotopic transplantation;outcome assessment;adolescent;priority journal;propensity score;prosthetic valve endocarditis;prosthetic valve thrombosis;pulmonary valve replacement;pulmonary valve stenosis;retrospective study;school child;structural valve degeneration;valvular heart disease;stentless bioprosthetic valve;heart valve bioprosthesisMedtronic Freestyle;postoperative hemorrhage;allograft;article
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

86
checked on Mar 20, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.